Why Astrazeneca (AZN) Dipped More Than Broader Market Today

Astrazeneca (AZN) ended the recent trading session at $183.86, demonstrating a -3.04% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.66%. Shares of the pharmaceutical witnessed a gain of 6.86% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 27, 2026. The company is predicted to post an EPS of $2.52, indicating a 15.6% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $15.27 billion, indicating a 5.65% upward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $10.29 per share and a revenue of $63.18 billion, demonstrating changes of +12.34% and +7.56%, respectively, from the preceding year. Investors might also notice recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.33% upward. Currently, Astrazeneca is carrying a Zacks Rank of #2 (Buy). Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.43. This valuation marks a discount compared to its industry average Forward P/E of 23.76. It is also worth noting that AZN currently has a PEG ratio of 1.5. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.72. The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 155, placing it within the bottom 37% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks